These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 33371456)

  • 21. Arrested development: suppression of NK cell function in the tumor microenvironment.
    Riggan L; Shah S; O'Sullivan TE
    Clin Transl Immunology; 2021; 10(1):e1238. PubMed ID: 33456775
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional and metabolic targeting of natural killer cells to solid tumors.
    Wang J; Matosevic S
    Cell Oncol (Dordr); 2020 Aug; 43(4):577-600. PubMed ID: 32488848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Natural Killer Cells as Key Players of Tumor Progression and Angiogenesis: Old and Novel Tools to Divert Their Pro-Tumor Activities into Potent Anti-Tumor Effects.
    Bassani B; Baci D; Gallazzi M; Poggi A; Bruno A; Mortara L
    Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 30939820
    [No Abstract]   [Full Text] [Related]  

  • 24. NK Cell-Based Immunotherapy and Therapeutic Perspective in Gliomas.
    Pan C; Zhai Y; Li G; Jiang T; Zhang W
    Front Oncol; 2021; 11():751183. PubMed ID: 34765554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combining radiotherapy and NK cell-based therapies: The time has come.
    Baude J; Limagne E; Ladjohounlou R; Mirjolet C
    Int Rev Cell Mol Biol; 2023; 378():31-60. PubMed ID: 37438020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NK cells are never alone: crosstalk and communication in tumour microenvironments.
    Zhou Y; Cheng L; Liu L; Li X
    Mol Cancer; 2023 Feb; 22(1):34. PubMed ID: 36797782
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy.
    Hu Y; Tian ZG; Zhang C
    Acta Pharmacol Sin; 2018 Feb; 39(2):167-176. PubMed ID: 28880014
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
    Lin C; Zhang J
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy.
    Hawkins ER; D'Souza RR; Klampatsa A
    Biologics; 2021; 15():95-105. PubMed ID: 33883875
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CAR-NK for tumor immunotherapy: Clinical transformation and future prospects.
    Wang W; Jiang J; Wu C
    Cancer Lett; 2020 Mar; 472():175-180. PubMed ID: 31790761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Engineering Metabolism of Chimeric Antigen Receptor (CAR) Cells for Developing Efficient Immunotherapies.
    Mangal JL; Handlos JL; Esrafili A; Inamdar S; Mcmillian S; Wankhede M; Gottardi R; Acharya AP
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33807867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CAR-NK as a Rapidly Developed and Efficient Immunotherapeutic Strategy against Cancer.
    Włodarczyk M; Pyrzynska B
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined use of NK cells and radiotherapy in the treatment of solid tumors.
    Zheng W; Ling S; Cao Y; Shao C; Sun X
    Front Immunol; 2023; 14():1306534. PubMed ID: 38264648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CAR-NK cells for cancer immunotherapy: from bench to bedside.
    Zhang L; Meng Y; Feng X; Han Z
    Biomark Res; 2022 Mar; 10(1):12. PubMed ID: 35303962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advances in metabolic reprogramming of NK cells in the tumor microenvironment on the impact of NK therapy.
    Miao L; Lu C; Zhang B; Li H; Zhao X; Chen H; Liu Y; Cui X
    J Transl Med; 2024 Mar; 22(1):229. PubMed ID: 38433193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.
    Burger MC; Zhang C; Harter PN; Romanski A; Strassheimer F; Senft C; Tonn T; Steinbach JP; Wels WS
    Front Immunol; 2019; 10():2683. PubMed ID: 31798595
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer.
    Rezvani K; Rouce RH
    Front Immunol; 2015; 6():578. PubMed ID: 26635792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Next-Generation CEA-CAR-NK-92 Cells against Solid Tumors: Overcoming Tumor Microenvironment Challenges in Colorectal Cancer.
    Franzén AS; Boulifa A; Radecke C; Stintzing S; Raftery MJ; Pecher G
    Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Biological Role and Therapeutic Potential of NK Cells in Hematological and Solid Tumors.
    Velichinskii RA; Streltsova MA; Kust SA; Sapozhnikov AM; Kovalenko EI
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.